Nancy A. Melville

News

Myeloma: Isa-KRd Induction Shows High MRD Responses

Author:: Nancy A. Melville

Publish date: October 9, 2024

Interim analysis of first MIDAS trial findings shows “highest rate of response and MRD negativity to date.”

News

Daratumumab Quadruplet Supported Transplant-Ineligible MM

Author:: Nancy A. Melville

Publish date: October 3, 2024

A phase-3 study showed that adding daratumumab to VRd yields a primary endpoint of MRD negativity in patients newly diagnosed with myeloma.

News

Myeloma: Daratumumab Plus Lenalidomide Improves MRD Outcomes

Author:: Nancy A. Melville

Publish date: September 30, 2024

New research shows that adding daratumumab to maintenance therapy improves MRD and PFS outcomes in multiple myeloma.

News

SGLT2 Inhibitor Reduces Risk for Neurodegenerative Diseases in T2D

Author:: Nancy A. Melville

Publish date: September 16, 2024

Those receiving SGLT2i treatment had a 21% reduced risk for all-cause dementia and a 22% reduced risk for all-cause dementia and Parkinson’s diseas...

News

After Rapid Weight Loss, Monitor Antiobesity Drug Dosing

Author:: Nancy A. Melville

Publish date: August 15, 2024

Toxicities from excessive doses can have a range of detrimental effects; examine dosing following rapid weight loss.

News

LBCL: CAR T Benefits Both Young and Old

Author:: Nancy A. Melville

Publish date: July 26, 2024

Evidence shows that CAR T-cell therapy yields similar survival outcomes for both older and younger patients with large B-cell lymphoma.

News

Hemophilia: Novel Tx Also Cuts Bleeding in Kids

Author:: Nancy A. Melville

Publish date: July 22, 2024

For pediatric patients with hemophilia A, once-weekly factor VIII prophylaxis shows bleeding protection similar to that for adults.

News

What Should Be Prioritized in Managing Early Diabetes?

Author:: Nancy A. Melville

Publish date: July 3, 2024

ADA meeting debate on what to treat first in early diabetes included obesity, glucose, remission as priorities.

News

Hemophilia: Marstacimab Sustains Long-Term Bleeding Reduction

Author:: Nancy A. Melville

Publish date: June 26, 2024

In an interim analysis, this novel, weekly subcutaneous injection shows continued benefits in the prevention of bleeding in hemophilia A and B.

News

Pancreatic Gene Therapy: A ‘One-and-Done’ GLP-1 Treatment?

Author:: Nancy A. Melville

Publish date: June 26, 2024

A single-dose pancreatic gene therapy may compare with GLP-1 effect, a mouse model study finds.

News

DLBCL: Glofitamab Plus Chemo Boosts Survival

Author:: Nancy A. Melville

Publish date: June 20, 2024

The bispecific antibody glofitamab, combined with chemotherapy, significantly improves overall survival in second-line treatment of DLBCL.

News

APL: Should Chemo-Free Regimen Become New Standard?

Author:: Nancy A. Melville

Publish date: June 20, 2024

Fresh data indicates that the benefits of a chemo-free regimen also extend to the treatment of high-risk acute promyelocytic leukemia.

News

Myeloma: First-In-Class ADC Regimen Yields Key Benefits

Author:: Nancy A. Melville

Publish date: June 6, 2024

Patients with relapsed/refractory multiple myeloma show significant improvements in PFS when treated with an antibody-drug conjugate.

News

CML: Asciminib Bests Standard TKIs as Frontline Therapy

Author:: Nancy A. Melville

Publish date: June 3, 2024

For CML, this potent, highly selective TKI significantly improves molecular responses, reduces discontinuations versus standard TKIs.

News

Semaglutide Kidney Benefits Extend to Those Without Diabetes

Author:: Nancy A. Melville

Publish date: May 31, 2024

The kidney benefits observed in patients who are at high risk of kidney disease but do not yet have diabetes or chronic kidney disease is encouragi...